Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide and is especially common in East Asia. Although supportive treatments have improved, many patients still progress to end-stage renal disease. Nefecon, a targeted-release formulation of budesonide designed to act on the gut-associated lymphoid tissue (GALT), has been shown in clinical trials to reduce proteinuria and slow kidney function decline. However, real-world data on its effectiveness in Chinese patients are still limited.
This multicenter observational study enrolled Chinese adults with biopsy-confirmed IgAN, an estimated glomerular filtration rate (eGFR) of ≥30 mL/min/1.73 m², and 24-hour urinary total protein (UTP) of ≥1 g/day. All participants received oral Nefecon 16 mg once daily for 9 months. Study outcomes included changes in UTP and eGFR over a 15-month observation period. Logistic regression analysis was performed to identify factors associated with a ≥50% reduction in UTP at Month 12, including galactose-deficient IgA1 (Gd-IgA1) levels, age, baseline UTP, baseline eGFR, and the interval between renal biopsy and initiation of Nefecon. Safety events and concomitant medication use were also recorded.
A total of 91 patients were enrolled (Figure 1; mean age, 38.1 ± 9.7 years; 54.9% male). The mean baseline eGFR was 64.8 ± 28.4 mL/min/1.73 m², and the median UTP was 1.60 g/day. UTP levels decreased steadily after treatment, with a 22.8% reduction at Month 9 (P < 0.01) and a peak reduction of 40.0% at Month 12 (P < 0.001; Figure 2). At Month 12, 40.7% of patients achieved a ≥50% decrease in UTP, and 20.9% reached UTP < 0.5 g/day. Each additional month of Nefecon therapy increased the likelihood of achieving a ≥50% UTP reduction at Month 12 by 15% (OR = 1.15, 95% CI 1.09–1.22, P < 0.001; Figure 3). A reduction of ≥10% in serum Gd-IgA1 at Month 6 was independently associated with a ≥50% reduction in UTP at Month 12 (OR = 3.14, 95% CI 1.11–9.66, P = 0.036). eGFR showed a biphasic trend, with a transient increase at Month 3, a decline at Month 12, and partial recovery by Month 15.
In this real-world Chinese cohort, Nefecon treatment was associated with a gradual but sustained reduction in proteinuria and relatively stable renal function. An early decrease in serum Gd-IgA1 correlated with subsequent proteinuria response, suggesting its potential role as a pharmacodynamic biomarker. These findings provide real-world evidence supporting the effectiveness of Nefecon in Chinese patients with IgAN and may help guide its use in broader Asian populations.
